The healthcare research services provider will contribute $50m of the capital as an anchor investor and seek to fund China and US-based portfolio companies.
China-based healthcare research and development services company WuXi PharmaTech is looking to raise up to $250m for a new corporate venturing fund, Dow Jones reported yesterday.
WuXi PharmaTech will act as anchor investor for the new fund and will put up $50m of capital, according to a company report in April. It will target investments in US and China-based healthcare companies.
Founded in 2000, WuXi PharmaTech provides laboratory and manufacturing services for the pharmaceutical, biotechnology and medical device industries. The…